Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 16, pseudogene (RNU6-16P)
- Target
- RNU6-16P
- Molecular classification
- Other (pseudogene), Small nuclear RNA (snRNA) pseudogene
01
Overview
RNA, U6 small nuclear 16, pseudogene (RNU6-16P) is a nonfunctional genetic element derived from the canonical U6 small nuclear RNA gene family. U6 snRNAs are core components of the spliceosome and facilitate pre-mRNA splicing in eukaryotic nuclei[1]. Pseudogenes such as RNU6-16P arise via retrotransposition or duplication of functional snRNA genes and are incapable of forming the active RNA required for catalysis or spliceosomal assembly[3]. RNU6-16P does not participate in splicing and is not implicated as a molecular target in pharmacology or biotechnology. It is annotated in bioinformatics databases primarily as a marker of genomic events, not as a functional gene or therapeutic target[2][3].
- Other names
- RNU6-16PRNU6-16RNA, U6 small nuclear 16, pseudogeneU6 pseudogene 16
02
Mechanism of action
None (because it is not a therapeutic target and is nonfunctional)
03
Biological functions
None (as a pseudogene, it does not have an established biological function in splicing or other cellular processes; functional U6 snRNAs are involved in mRNA splicing[1], but RNU6-16P is a nonfunctional copy)
04
Disease associations
Other (pseudogene status means direct involvement in disease is not established)Pseudogenes can sometimes be markers of retrotransposition events and genome dynamics in cancer and other diseases, but there is no specific evidence for RNU6-16P[3][4]
05
Safety considerations
None (when not expressed or functional, safety considerations are not relevant)
06
Interacting drugs
None (no drugs are known to interact with this pseudogene)
07
Biomarkers
None (some pseudogenes can incidentally be used as markers in differential gene expression analyses, but there is no current evidence that RNU6-16P is used as a biomarker[4])
Beyond the preview
Go deeper on RNA, U6 small nuclear 16, pseudogene (RNU6-16P).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RNA, U6 small nuclear 16, pseudogene (RNU6-16P).